Navigation Links
Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer
Date:9/23/2009

se of cancer death among men after lung cancer. In 2009, an estimated 192,000 new cases are expected to be diagnosed, and approximately 27,000 men are expected to die from the disease. Prostate tumors that have stopped responding to, or are growing despite the use of, active hormone treatment strategies are characterized as castration-resistant. Patients with castration-resistant prostate cancer have a poor prognosis and few treatment options.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, Medivation is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. The companies are also conducting a Phase 3 trial of dimebon in Huntington disease. A Phase 3 clinical trial of MDV3100 in patients with castration-resistant prostate cancer is under way. For more information, please visit us at http://www.medivation.com.

This press release contains forward-looking statements, including statements regarding the potential clinical benefits of MDV3100 in various patient populations, and development plans and goals for MDV3100, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements containe
'/>"/>

SOURCE Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
2. Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimers Disease
3. Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
4. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
5. Medivation Announces Publication in The Lancet of Dimebon Pivotal Trial Results in Alzheimers Disease
6. Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntingtons Disease
7. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
8. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
9. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
10. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
11. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 According to Millennium Research ... market intelligence, although the US minimally invasive spinal ... growth rate of over 12% through 2014, reimbursement ... the overall market, which previously had been forecast ... for Minimally Invasive Spine Technologies 2010 ...
(Date:12/16/2009)... HDT Engineered Technologies (HDT), a leader ... a principal subcontractor for the mechanical development of ... new anthropromorphic arm technology that will give patients ... hand, including a sense of touch. ,, ... Agency (DARPA) Revolutionizing Prosthetics 2009 (RP2009) project, the ...
(Date:12/16/2009)... Accuray Incorporated (Nasdaq: ARAY ), a global leader ... president and chief executive officer, Euan S. Thomson, Ph.D., ... Morgan Healthcare Conference in San Francisco on Wednesday, January ... ,, A live webcast of each presentation will be ... Company,s Web site at http://www.accuray.com . The ...
Breaking Medicine Technology:Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 2Reimbursement Difficulties With TranS1's AxiaLIF and NuVasive's XLIF Have Sceptics Talking 3HDT Develops Robotic Arm Technology for DARPA's Revolutionizing Prosthetics 2009 Program 2Accuray Incorporated to Present at 28th Annual J. P. Morgan Healthcare Conference 2Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 15083 1Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 15083 2Vivakor Announces Additions to Board of Directors and Scientific Advisory Board 15083 3Despite Limited Capital Equipment Purchases In 2009 The Global Powered Surgical Instrument Market Held Its Value At 24800 Million 6792 1Despite Limited Capital Equipment Purchases In 2009 The Global Powered Surgical Instrument Market Held Its Value At 24800 Million 6792 2Despite Limited Capital Equipment Purchases In 2009 The Global Powered Surgical Instrument Market Held Its Value At 24800 Million 6792 3VidaySalud com 28TM 29 Reaches 1 000 000 Page Views In its First Six Months of Operation 6788 1VidaySalud com 28TM 29 Reaches 1 000 000 Page Views In its First Six Months of Operation 6788 2
... Follow-up RAS data presented at ASCO , HORSOLM, ... presentation titled "RAS peptide vaccination in resected,pancreatic cancer ... term survival" at ASCO's (American Society of Clinical,Oncology) ... 23 resected pancreatic cancer patients,immunized in the period ...
... Positive data on subcutaneous administration show potential for,new ... June 04, 2007 /PRNewswire-FirstCall/ -- Millennium,Pharmaceuticals, Inc. today ... market-leading therapy for patients with,multiple myeloma (MM) who ... include results from a Phase II trial for ...
Other Medicine Technology:Pharmexa A/S (DK) - Long lasting immune response and survival to,RAS vaccine 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 2New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 3New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 4New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 5New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 6New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma 7
(Date:12/17/2009)... the last few weeks there has been an increase ... by e cigarette opposition in an attempt to scare ... the tactics of these groups when the evidence clearly ... to tobacco according to several studies, lab reports and ... the world. ,, Special interest groups appear to ...
(Date:12/17/2009)... Dec. 17 John Howell, CEO ... of Arrayit Corporation (OTC Bulletin Board: ARYC), ... for commercialization of its microarray-based OvaDx(TM) ... is currently advancing through late-stage development - ... exclusively to the Company by Arrayit Corporation. ...
(Date:12/17/2009)... revealing portrait of the nearly one-in-three American adults who serve as ... ... 17, 2009 -- The National Alliance on Mental Illness (NAMI) praises ... offers a revealing portrait of the nearly one-in-three American adults who ... on interviews with 1,480 caregivers chosen at random and offers a ...
(Date:12/17/2009)... search engines like Google Local and in front of their local ... Local Registration service offered by New Orleans based Webtyde Internet Marketing. ... ... -- In order to be competitive locally and nationally, businesses must ... a local map section in a major search engine, a business ...
(Date:12/17/2009)... marketing techniques, life coaching company puts free i-phone & ... http://itunes.apple.com/us/app/attainment-life-management/id345691804?mt=8 . For the Free download. , ... ... -- Utah based Attainment Life Management & Coaching is ... everything in life simplified into one little hand held ...
Breaking Medicine News(10 mins):Health News:Special Interest Deceptions Continue to Rampant About Electronic Cigarettes 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 2Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 3Health News:Arrayit Diagnostics to Bring First Pre-Symptomatic Ovarian Cancer Blood Test to Multi-Billion Dollar Diagnostic Market in 2010 4Health News:NAMI Applauds New Report on Caregiving 2Health News:NAMI Applauds New Report on Caregiving 3Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2Health News:Attainment Life Management & Coaching has just Debuted its Free Application for I-Phone and I-Touch Users 2
... Gorakhpur District are grappling to fight against a deadly viral ... children in the past five months. ,Dr. A.K.Rathi, Head ... run by the college has received over 100 patients since ... of the disease. ,Dr. M.P.Singh, Joint-Director ...
... The battle against HIV/AIDS is becoming grimmer by the day. ... could be infected with HIV/AIDS by 2015 if the ... ,"We should be winning in HIV prevention," Jennifer Kates, ... Family Foundation, said Friday. ,But the reality is ...
... rashes. Prescription medications including steroid creams that ease ... ,When over five million Americans suffer from that skin ... response, especially when backed by some kind of evidence.,And ... though experts are skeptical. ,"We can control ...
... turning its excess wine produce into bioethanol. ... ,Commission officials have, however, made it clear ... subsidize such a move. ,Michael Mann, commission spokesman ... to do would be to stop the excess wine from ...
... a growing segment of the population but vote less ... favor Democrats over Republicans, said a study published Friday. ... older now account for 45.2 percent of the US ... Vote said in its study titled "Unmarried America 2007: ...
... that women with at least three sites of cellular atypia ... than average women to develop breast cancer. , ... atypia) in breast tissue is a major risk factor for ... diagnosed with atypia are considered at high risk. ...
Other Medicine News:Health News:Expand HIV/AIDS Prevention Programs, Experts Stress 2Health News:Expand HIV/AIDS Prevention Programs, Experts Stress 3Health News:Experts Critical of a New OTC Product to Treat Psoriasis 2Health News:Experts Critical of a New OTC Product to Treat Psoriasis 3Health News:Single Americans Vote Less, but Lean Towards Democrats: Study 2Health News:Women With Atypia Nearly Eight Times More Likely to Develop Breast Cancer 2
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Supplied sterile in peel-open packages. Intended for one-time use....
... and exchange in endourological procedures. The increased ... allows utilization of an extra heavy duty ... very flexible tip. The proximal end of ... coiled wire guide manufactured by Cook®. Supplied ...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: